Cork MJ, Thaçi D, Eichenfield LF, et al. - In adolescents with moderate-to-severe atopic dermatitis (AD), researchers studied the pharmacokinetic profile, safety and effectiveness of dupilumab, monoclonal antibody inhibiting IL-4/IL-13 signalling. It was a global, multicentre, phase IIa, open-label, ascending-dose, sequential cohort study with a phase III open-label extension (OLE) in moderate-to-severe AD adolescents. Forty adolescents took dupilumab in the phase IIa study; 36 recruited in the OLE. The pharmacokinetic profile of dupilumab in adolescents with moderate to severe AD was similar to that in adults. This 52-week safety and efficacy data support this patient population's long-term use of dupilumab. Nasopharyngitis and AD exacerbation were the most common treatment-emergent adverse events.